ZIMV Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -1.31% compared to ZimVie's net margin of --. ZimVie's return on equity of -4.97% beat Perspective Therapeutics's return on equity of --.

ZimVie has a consensus price target of $11.67, signalling upside risk potential of 29.63%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 254.45%. Given that Perspective Therapeutics has higher upside potential than ZimVie, analysts believe Perspective Therapeutics is more attractive than ZimVie.

ZimVie has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

ZimVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZimVie pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

ZimVie quarterly revenues are $112M, which are larger than Perspective Therapeutics quarterly revenues of --. ZimVie's net income of -$1.5M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, ZimVie's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZimVie is 0.56x versus 28.05x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of -1.31% compared to ZimVie's net margin of -5.14%. ZimVie's return on equity of -4.97% beat Integer Holdings's return on equity of 4.85%.

ZimVie has a consensus price target of $11.67, signalling upside risk potential of 29.63%. On the other hand Integer Holdings has an analysts' consensus of $148.75 which suggests that it could grow by 24%. Given that ZimVie has higher upside potential than Integer Holdings, analysts believe ZimVie is more attractive than Integer Holdings.

ZimVie has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Integer Holdings has a beta of 0.980, suggesting its less volatile than the S&P 500 by 1.988%.

ZimVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZimVie pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

ZimVie quarterly revenues are $112M, which are smaller than Integer Holdings quarterly revenues of $437.4M. ZimVie's net income of -$1.5M is higher than Integer Holdings's net income of -$22.5M. Notably, ZimVie's price-to-earnings ratio is -- while Integer Holdings's PE ratio is 56.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZimVie is 0.56x versus 2.42x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -1.31% compared to ZimVie's net margin of -2201.34%. ZimVie's return on equity of -4.97% beat VolitionRX's return on equity of --.

ZimVie has a consensus price target of $11.67, signalling upside risk potential of 29.63%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 340.32%. Given that VolitionRX has higher upside potential than ZimVie, analysts believe VolitionRX is more attractive than ZimVie.

ZimVie has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

ZimVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZimVie pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

ZimVie quarterly revenues are $112M, which are larger than VolitionRX quarterly revenues of $246.4K. ZimVie's net income of -$1.5M is higher than VolitionRX's net income of -$5.4M. Notably, ZimVie's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZimVie is 0.56x versus 46.02x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -1.31% compared to ZimVie's net margin of 0.18%. ZimVie's return on equity of -4.97% beat Xtant Medical Holdings's return on equity of -26.62%.

ZimVie has a consensus price target of $11.67, signalling upside risk potential of 29.63%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 167.18%. Given that Xtant Medical Holdings has higher upside potential than ZimVie, analysts believe Xtant Medical Holdings is more attractive than ZimVie.

ZimVie has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

ZimVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZimVie pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

ZimVie quarterly revenues are $112M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. ZimVie's net income of -$1.5M is lower than Xtant Medical Holdings's net income of $58K. Notably, ZimVie's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZimVie is 0.56x versus 0.73x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.